Which one is better, Secukinumab or Adalimumab?

Secukinumab and adalimumab are two different prescription drugs with different therapeutic effects. Secukinumab is a humanizedIgG1 monoclonal antibody that can be used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and enthesitis-related arthritis. Common side effects include upper respiratory tract infection, oral herpes, runny nose and diarrhea. Adalimumab is a humanized monoclonal antibody of IgG1 that binds to soluble ST2 receptors and is commonly used to treat moderate and severe plaque psoriasis. Common adverse reactions include infusion reactions and upper respiratory tract infections.